Back to Search
Start Over
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- Source :
- PR Newswire. January 6, 2021
- Publication Year :
- 2021
-
Abstract
- - DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.647555541